 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 02/22/2001 | | | | New Study Confirms Again the Reliability and Efficacy of Nymox's AlzheimAlert™ Test
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
MAYWOOD, NJ (February 22, 2001) – Nymox Pharmaceutical Corporation (NASDAQ: NYMX) – A new study confirming the reliability and efficacy of Nymox’s AlzheimAlert™ test will be presented on Sunday, February 25 at the 14th Annual Meeting of the American Association for Geriatric Psychiatry in San Francisco. Based on a coded double blind study of urine samples from 47 patients with Alzheimer’s disease and 32 aged matched normal controls, the study showed that the AlzheimAlert™ test could distinguish between Alzheimer’s disease patients and normals with a high degree of accuracy. |
| 02/15/2001 | | | | Prestigious Publication Confirms the Significance of Nymox's Alzheimer's Disease Marker
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
MAYWOOD, NJ (February 15, 2001) — Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced that a new study in the latest issue of the Journal of Neuropathology and Experimental Neurology (Vol. 60, No.2, pp. 195-207 ), a prestigious peer-reviewed medical journal, provides further evidence of the key role played by the brain protein which the Nymox AlzheimAlert™ test detects in patients with Alzheimer’s disease. The study was authored by Dr. Suzanne de la Monte and Dr. Jack Wands of Brown University. |
| 02/08/2001 | | | | Nymox's AlzheimAlert™ Test Gaining Recognition and Wide Medical Acceptance
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
MAYWOOD, NJ (February 8, 2001) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that its AlzheimAlert™ urinary test has attracted increasing interest and recognition from practising physicians, multinational pharmaceutical companies and the media. AlzheimAlert™ is a state of the art test for physicians to aid to the diagnosis of Alzheimer’s disease. The test which costs $295 is the latest generation of Nymox’s NTP technology which detects elevated levels of a brain protein (NTP) known to be elevated in the urine of patients with Alzheimer’s disease. |
| 01/31/2001 | | | | Nymox Announces E. Coli Collaboration with Prestigious Veterinary Institution
topic: R&D: E coli and Other Antibacterial Treatments
January 31, 2001: Nymox Pharmaceutical Corporation announced today its collaboration with the Faculty of Veterinary Medicine at the University of Montreal to study animal treatments for E. coli O157:H7, the deadly bacteria implicated in contamination of meat and other food and drink products and of drinking water supplies. |
| 01/23/2001 | | | | Nymox and Biophage to Co-Develop Antimicrobial Treatments
topic: R&D: E coli and Other Antibacterial Treatments
January 23, 2001: Nymox Pharmaceutical Corporation announced today that it has signed a letter of intent with Biophage Inc., a Montreal company, to collaborate on the development of novel antimicrobial treatments and applications. |
| 01/11/2001 | | | | Nymox's E. Coli Inhibitor Effective in Independent Tests
topic: R&D: E coli and Other Antibacterial Treatments
January 11, 2001: Nymox Pharmaceutical Corporation announced today that tests conducted at the Department of Food Science at the University of Manitoba demonstrated that Nymox’s novel proprietary antibacterial agent, NXC 4720, completely eliminated E. coli O157:H7 in a laboratory model of a livestock gut. |
| 01/09/2001 | | | | Nymox Launches New Internet Presence
topic: Marketing
MAYWOOD, NJ (January 9, 2001) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced the launch of its newly designed web site at www.nymox.com. The site incorporates state-of-the-art software features that will allow for user friendly services such as on-line ordering of Nymox products and up-to-date communications. |
| 12/20/2000 | | | | Nymox Management and Board of Directors Announce Share Purchase
topic: Financial
MAYWOOD, NJ (December 20, 2000) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that Nymox’s management and members of its Board of Directors intend to purchase in the open market up to 1,000,000 shares of Nymox’s outstanding Common Stock. This intention reflects their common belief about the promising future of the company, which is now marketing two products to augment a growing research and development pipeline. |
| 12/18/2000 | | | | Nymox Announces New Alzheimer Drug Screening Developments
topic: R&D: Spherons and Alzheimer's Disease
December 18, 2000: Nymox Pharmaceutical Corporation announced today that its researchers have devised a unique new high throughput screening system for Alzheimer’s disease (AD) therapeutics. The Company employed its Spheron technology base to develop the new rapid drug screening and testing methodologies. |
| 12/14/2000 | | | | Nymox to be Featured on American Medical Review
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
Nymox announced today that the company has been selected to be profiled in a story about the AlzheimAlert™ test on the American Medical Review Series. The Series is hosted by Morley Safer and featured stories on various technologies, products or services that have significantly contributed on a national and/or international level to the advancement of the healthcare industry. |
|